Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line

Masakazu Chikamori; Nagio Takigawa; Katsuyuki Kiura; Masahiro Tabata; Takuo Shibayama; Yoshihiko Segawa; Hiroshi Ueoka; Taisuke Ohnoshi; Mitsune Tanimoto

Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line

Masakazu Chikamori, Nagio Takigawa, Katsuyuki Kiura, Masahiro Tabata, Takuo Shibayama, Yoshihiko Segawa, Hiroshi Ueoka, Taisuke Ohnoshi, Mitsune Tanimoto

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

Irinotecan is one of the most active drugs used in the treatment of small cell lung cancer (SCLC). 7-Ethyl-10-hydroxy-camptothecin (SN-38) is an active metabolite of irinotecan. We established an SN-38-resistant subline (SBC-3/SN-38) by continuous exposure of SN-38 to a human SCLC cell line, SBC-3. Using the 3-[4, 5-dimethyl-thiazol-2-yl] 2, 5-diphenyltetrazolium bromide assay, we evaluated the cytotoxicity of 17 anticancer agents. The SBC-3/SN-38 cells were 73-fold more resistant than the parental SBC-3 cells to SN-38 and showed cross-resistance not only to topoisomerase (topo) I inhibitors (irinotecan and topotecan), but also to topo II inhibitors (adriamycin and etoposide), antimicrotubule agents (vincristine, vindesine, vinorelbine and docetaxel), alkylating agents (cyclophosphamide and ifosfamide), platinum (cisplatin and carboplatin) and antifolate (methotrexate). Interestingly, the resistant subline reserved the sensitivity to bleomycin and 5-fluorouracil. The SBC-3/SN-38 cells had decreased topo I and II activity compared to the parent cells. The SN-38-resistant cell line, SBC-3/SN-38, will be useful to elucidate the mechanism of action of the topo I inhibitors.

Original language	English
Pages (from-to)	3911-3916
Number of pages	6
Journal	Anticancer research
Volume	24
Issue number	6
Publication status	Published - Nov 2004

Keywords

Drug resistance
Irinotecan
Small cell lung cancer
Topoisomerase

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Fingerprint Dive into the research topics of 'Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line'. Together they form a unique fingerprint.

Cite this

Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line. / Chikamori, Masakazu; Takigawa, Nagio; Kiura, Katsuyuki ; Tabata, Masahiro; Shibayama, Takuo; Segawa, Yoshihiko; Ueoka, Hiroshi; Ohnoshi, Taisuke; Tanimoto, Mitsune.

In: Anticancer research, Vol. 24, No. 6, 11.2004, p. 3911-3916.

Research output: Contribution to journal › Article › peer-review

@article{9b0bcf9877834d54bafcbc9a36cf93f6,

title = "Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line",

abstract = "Irinotecan is one of the most active drugs used in the treatment of small cell lung cancer (SCLC). 7-Ethyl-10-hydroxy-camptothecin (SN-38) is an active metabolite of irinotecan. We established an SN-38-resistant subline (SBC-3/SN-38) by continuous exposure of SN-38 to a human SCLC cell line, SBC-3. Using the 3-[4, 5-dimethyl-thiazol-2-yl] 2, 5-diphenyltetrazolium bromide assay, we evaluated the cytotoxicity of 17 anticancer agents. The SBC-3/SN-38 cells were 73-fold more resistant than the parental SBC-3 cells to SN-38 and showed cross-resistance not only to topoisomerase (topo) I inhibitors (irinotecan and topotecan), but also to topo II inhibitors (adriamycin and etoposide), antimicrotubule agents (vincristine, vindesine, vinorelbine and docetaxel), alkylating agents (cyclophosphamide and ifosfamide), platinum (cisplatin and carboplatin) and antifolate (methotrexate). Interestingly, the resistant subline reserved the sensitivity to bleomycin and 5-fluorouracil. The SBC-3/SN-38 cells had decreased topo I and II activity compared to the parent cells. The SN-38-resistant cell line, SBC-3/SN-38, will be useful to elucidate the mechanism of action of the topo I inhibitors.",

keywords = "Drug resistance, Irinotecan, Small cell lung cancer, Topoisomerase",

author = "Masakazu Chikamori and Nagio Takigawa and Katsuyuki Kiura and Masahiro Tabata and Takuo Shibayama and Yoshihiko Segawa and Hiroshi Ueoka and Taisuke Ohnoshi and Mitsune Tanimoto",

year = "2004",

month = nov,

language = "English",

volume = "24",

pages = "3911--3916",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "6",

}

TY - JOUR

T1 - Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line

AU - Chikamori, Masakazu

AU - Takigawa, Nagio

AU - Kiura, Katsuyuki

AU - Tabata, Masahiro

AU - Shibayama, Takuo

AU - Segawa, Yoshihiko

AU - Ueoka, Hiroshi

AU - Ohnoshi, Taisuke

AU - Tanimoto, Mitsune

PY - 2004/11

Y1 - 2004/11

N2 - Irinotecan is one of the most active drugs used in the treatment of small cell lung cancer (SCLC). 7-Ethyl-10-hydroxy-camptothecin (SN-38) is an active metabolite of irinotecan. We established an SN-38-resistant subline (SBC-3/SN-38) by continuous exposure of SN-38 to a human SCLC cell line, SBC-3. Using the 3-[4, 5-dimethyl-thiazol-2-yl] 2, 5-diphenyltetrazolium bromide assay, we evaluated the cytotoxicity of 17 anticancer agents. The SBC-3/SN-38 cells were 73-fold more resistant than the parental SBC-3 cells to SN-38 and showed cross-resistance not only to topoisomerase (topo) I inhibitors (irinotecan and topotecan), but also to topo II inhibitors (adriamycin and etoposide), antimicrotubule agents (vincristine, vindesine, vinorelbine and docetaxel), alkylating agents (cyclophosphamide and ifosfamide), platinum (cisplatin and carboplatin) and antifolate (methotrexate). Interestingly, the resistant subline reserved the sensitivity to bleomycin and 5-fluorouracil. The SBC-3/SN-38 cells had decreased topo I and II activity compared to the parent cells. The SN-38-resistant cell line, SBC-3/SN-38, will be useful to elucidate the mechanism of action of the topo I inhibitors.

AB - Irinotecan is one of the most active drugs used in the treatment of small cell lung cancer (SCLC). 7-Ethyl-10-hydroxy-camptothecin (SN-38) is an active metabolite of irinotecan. We established an SN-38-resistant subline (SBC-3/SN-38) by continuous exposure of SN-38 to a human SCLC cell line, SBC-3. Using the 3-[4, 5-dimethyl-thiazol-2-yl] 2, 5-diphenyltetrazolium bromide assay, we evaluated the cytotoxicity of 17 anticancer agents. The SBC-3/SN-38 cells were 73-fold more resistant than the parental SBC-3 cells to SN-38 and showed cross-resistance not only to topoisomerase (topo) I inhibitors (irinotecan and topotecan), but also to topo II inhibitors (adriamycin and etoposide), antimicrotubule agents (vincristine, vindesine, vinorelbine and docetaxel), alkylating agents (cyclophosphamide and ifosfamide), platinum (cisplatin and carboplatin) and antifolate (methotrexate). Interestingly, the resistant subline reserved the sensitivity to bleomycin and 5-fluorouracil. The SBC-3/SN-38 cells had decreased topo I and II activity compared to the parent cells. The SN-38-resistant cell line, SBC-3/SN-38, will be useful to elucidate the mechanism of action of the topo I inhibitors.

KW - Drug resistance

KW - Irinotecan

KW - Small cell lung cancer

KW - Topoisomerase

UR - http://www.scopus.com/inward/record.url?scp=14944382966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14944382966&partnerID=8YFLogxK

M3 - Article

C2 - 15736431

AN - SCOPUS:14944382966

VL - 24

SP - 3911

EP - 3916

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -

Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Cite this